Guggenheim Maintains Buy on UroGen Pharma, Raises Price Target to $42

Benzinga Newsdesk www.benzinga.com Positive 79.6%

Neg 0% Neu 0% Pos 79.6%

Guggenheim analyst Brad Canino maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the price target from $32 to $42.